Confidentiality vs. Transparency: Germany’s Drug Price Dilemma Unpacked
Are confidential drug prices coming to Germany? Until now, the reimbursed prices of drugs are in the public domain (Lauer Taxe), but
Category: News and updates
G-BA decisions from 20 June 2024
Here are the G-BA decisions from the G-BA meeting held on 20 June 2024 on the early benefit assessments of Jemperli, Ayvakyt,
G-BA decisions from 6 June 2024
Here are the G-BA decisions from the G-BA meeting held on 6 June 2024 on the early benefit assessments of Prevymis, Ebglyss,
G-BA decisions from 16 May 2024
Here are the G-BA decisions from the G-BA meeting held on 16 May 2024 on the early benefit assessments of Darzalex, Kimmtrak,
Determining the Reimbursed Price for Pharmaceuticals in Germany
Introduction Entering the dynamic realm of pharmaceutical pricing in Germany, we find ourselves immersed in a landscape defined by regulations, negotiations, price